Introduction: The underlying causes of stillbirth are heterogeneous and in many cases unexplained. Our aim was to conclude clinical results from karyotype and quantitative fluorescence-polymerase chain reaction (QF-PCR) analysis of all stillbirths occurring in Stockholm County between 2008 and 2012. By screening a subset of cases, we aimed to study the possible benefits of chromosomal microarray (CMA) in the analysis of the etiology of stillbirth. Methods: During 2008-2012, 481 stillbirths in Stockholm County were investigated according to a clinical protocol including karyotype or QF-PCR analysis. CMA screening was performed on a subset of 90 cases, corresponding to all stillbirths from 2010 without a genetic diagnosis. Results: Chromosomal aberrations were detected by karyotype or QF-PCR analysis in 7.5% of the stillbirths. CMA analysis additionally identified two known syndromes, one aberration disrupting a known disease gene, and 26 variants of unknown significance. Furthermore, CMA had a significantly higher success rate than karyotyping (100 vs. 80%, p < 0.001). Discussion: In the analysis of stillbirth, conventional karyotyping is prone to failure, and QF-PCR is a useful complement. We show that CMA has a higher success rate and aberration detection frequency than these methods, and conclude that CMA is a valuable tool for identification of chromosomal aberrations in stillbirth.

Keywords:
Chromosomal abnormalities, Comparative genomic hybridization, Cytogenetics, Fetal karyotype, Intrauterine death, Maternal age, Quantitative fluorescent-polymerase chain reaction
1.
Petersson K, Bremme K, Bottinga R, Hofsjo A, Hulthen-Varli I, Kublickas M, Norman M, Papadogiannakis N, Wanggren K, Wolff K: Diagnostic evaluation of intrauterine fetal deaths in Stockholm 1998-99. Acta Obstet Gynecol Scand 2002;81:284-292.
2.
Varli IH, Petersson K, Bottinga R, Bremme K, Hofsjo A, Holm M, Holste C, Kublickas M, Norman M, Pilo C, Roos N, Sundberg A, Wolff K, Papadogiannakis N: The Stockholm classification of stillbirth. Acta Obstet Gynecol Scand 2008;87:1202-1212.
3.
Wapner RJ: Genetics of stillbirth. Clin Obstet Gynecol 2010;53:628-634.
4.
Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker H, Hamid R, Hannig V, Abdel-Hamid H, Bader P, McCracken E, Niyazov D, Leppig K, Thiese H, Hummel M, Alexander N, Gorski J, Kussmann J, Shashi V, Johnson K, Rehder C, Ballif BC, Shaffer LG, Eichler EE: A copy number variation morbidity map of developmental delay. Nat Genet 2011;43:838-846.
5.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-764.
6.
Reddy UM, Page GP, Saade GR, Silver RM, Thorsten VR, Parker CB, Pinar H, Willinger M, Stoll BJ, Heim-Hall J, Varner MW, Goldenberg RL, Bukowski R, Wapner RJ, Drews-Botsch CD, O'Brien BM, Dudley DJ, Levy B, Network NSCR: Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 2012;367:2185-2193.
7.
Mann K, Donaghue C, Fox SP, Docherty Z, Ogilvie CM: Strategies for the rapid prenatal diagnosis of chromosome aneuploidy. Eur J Hum Genet 2004;12:907-915.
8.
Donaghue C, Roberts A, Mann K, Ogilvie CM: Development and targeted application of a rapid QF-PCR test for sex chromosome imbalance. Prenat Diagn 2003;23:201-210.
9.
Gijsbers AC, Schoumans J, Ruivenkamp CA: Interpretation of array comparative genome hybridization data: a major challenge. Cytogenet Genome Res 2011;135:222-227.
10.
Posch MG, Waldmuller S, Muller M, Scheffold T, Fournier D, Andrade-Navarro MA, De Geeter B, Guillaumont S, Dauphin C, Yousseff D, Schmitt KR, Perrot A, Berger F, Hetzer R, Bouvagnet P, Ozcelik C: Cardiac α-myosin (MYH6) is the predominant sarcomeric disease gene for familial atrial septal defects. PLoS One 2011;6:e28872.
11.
Granados-Riveron JT, Ghosh TK, Pope M, Bu'Lock F, Thornborough C, Eason J, Kirk EP, Fatkin D, Feneley MP, Harvey RP, Armour JA, David Brook J: Alpha-cardiac myosin heavy chain (MYH6) mutations affecting myofibril formation are associated with congenital heart defects. Hum Mol Genet 2010;19:4007-4016.
12.
Elsea SH, Girirajan S: Smith-Magenis syndrome. Eur J Hum Genet 2008;16:412-421.
13.
Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ, Autism C: Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008;358:667-675.
14.
Fernandez BA, Roberts W, Chung B, Weksberg R, Meyn S, Szatmari P, Joseph-George AM, Mackay S, Whitten K, Noble B, Vardy C, Crosbie V, Luscombe S, Tucker E, Turner L, Marshall CR, Scherer SW: Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. J Med Genet 2010;47:195-203.
15.
Crespi BJ, Crofts HJ: Association testing of copy number variants in schizophrenia and autism spectrum disorders. J Neurodev Disord 2012;4:15.
16.
Shinawi M, Liu P, Kang SH, Shen J, Belmont JW, Scott DA, Probst FJ, Craigen WJ, Graham BH, Pursley A, Clark G, Lee J, Proud M, Stocco A, Rodriguez DL, Kozel BA, Sparagana S, Roeder ER, McGrew SG, Kurczynski TW, Allison LJ, Amato S, Savage S, Patel A, Stankiewicz P, Beaudet AL, Cheung SW, Lupski JR: Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 2010;47:332-341.
17.
McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PI, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E, Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D: Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 2008;40:1166-1174.
18.
Jun G, Moncaster JA, Koutras C, Seshadri S, Buros J, McKee AC, Levesque G, Wolf PA, St George-Hyslop P, Goldstein LE, Farrer LA: Delta-catenin is genetically and biologically associated with cortical cataract and future Alzheimer-related structural and functional brain changes. PLoS One 2012;7:e43728.
19.
Medina M, Marinescu RC, Overhauser J, Kosik KS: Hemizygosity of δ-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome. Genomics 2000;63:157-164.
20.
Hoffman MC, Jeffers S, Carter J, Duthely L, Cotter A, Gonzalez-Quintero VH: Pregnancy at or beyond age 40 years is associated with an increased risk of fetal death and other adverse outcomes. Am J Obstet Gynecol 2007;196:e11-e13.
21.
O'Leary CM, Bower C, Knuiman M, Stanley FJ: Changing risks of stillbirth and neonatal mortality associated with maternal age in Western Australia, 1984-2003. Paediatr Perinat Epidemiol 2007;21:541-549.
22.
Flenady V, Koopmans L, Middleton P, Froen JF, Smith GC, Gibbons K, Coory M, Gordon A, Ellwood D, McIntyre HD, Fretts R, Ezzati M: Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet, 2011;377:1331-1340.
23.
Kenny LC, Lavender T, McNamee R, O'Neill SM, Mills T, Khashan AS: Advanced maternal age and adverse pregnancy outcome: evidence from a large contemporary cohort. PLoS One 2013;8:e56583.
24.
Reddy UM, Ko CW, Willinger M: Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am J Obstet Gynecol 2006;195:764-770.
25.
Rosenstein MG, Cheng YW, Snowden JM, Nicholson JM, Caughey AB: Risk of stillbirth and infant death stratified by gestational age. Obstet Gynecol 2012;120:76-82.
26.
Bhattacharya S, Prescott GJ, Black M, Shetty A: Recurrence risk of stillbirth in a second pregnancy. BJOG 2010;117:1243-1247.
27.
Sharma PP, Salihu HM, Kirby RS: Stillbirth recurrence in a population of relatively low-risk mothers. Paediatr Perinat Epidemiol 2007;21(suppl 1):24-30.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.